Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Normal Adult Volunteers


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04842045

Organisation Name: University of Wisconsin, Madison

Overal Status: Recruiting

Start Date: May 21, 2021

Last Update: June 3, 2021

Lead Sponsor: University of Wisconsin, Madison

Brief Summary: The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin. This pilot dosing study (PILOT RECAP) is designed to determine the optimal dose of midazolam that allows a psychedelic experience to occur while inducing amnesia for the experience. This is an essential step required for subsequent evaluation of the role of memory for the psychedelic experience in the antidepressant effects of psilocybin in the full RECAP study.

Conditions:
  • Psychedelic Experiences
  • Amnesia


Total execution time in seconds: 0.23987007141113